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Currently many women from families with a high
risk of breast cancer due to a familial or genetic
predisposition,  including  carriers  of  a BRCA1/2
germline mutation, opt for intensive surveillance [1].
Several guidelines advise screening by mammography
and clinical breast examination. However, the value of
this screening scheme in women that often start
screening under the age of 40 has never been proven.
There  are  indications  that  the  sensitivity  of
mammography is especially low in carriers of a BRCA1
or BRCA2 mutation [2, 3]. This is the main reason why
the value of MRI screening is being investigated in
various family cancer clinics worldwide. To date only
preliminary data from small studies are available about
the effectiveness of this MRI screening [4-6]. 
In these preliminary studies, MRI appears to be
a more sensitive screening method than mammography,
but this does not mean that it detects breast cancer at
an earlier stage. It might be expected that MRI can detect
breast cancer at an earlier stage than mammography.
However, no study has been published that compares
the tumour stage of patients detected within an MRI
screening  programme  with  that  of  comparable
symptomatic patients. As stated by Narod, the main goal
of screening is a stage shift towards earlier breast cancer
diagnosis that might lead to a reduction in breast cancer
mortality, against acceptable side effects. While the high
financial costs are mentioned by Narod, many other
negative effects of MRI screening have been described.
For instance, some studies described a specificity much
lower  as  compared  to  mammography,  causing
unnecessary additional investigations. These negative
effects should be taken into account when making
a decision to use a new screening tool. 
To date no longer-term prospective studies with
data about the potential of MRI to diagnose breast
cancer at an earlier stage, the possible reduction of
breast cancer mortality and the cost-effectiveness are
available. These data can be expected from several
ongoing studies in the near future [7, 8]. In this respect
we agree with Møller that only when these data are
available definitive and evidence-based advice about
screening in high risk women can be given. 
In the meantime we advise, as Narod and Møller,
to consider MRI screening in high risk women in
addition to the routine screening program, especially
in women where mammography screening has the
smallest effect, such as mutation carriers, until we
have results from large prospective studies. 
R Re ef fe er re en nc ce es s
1. Meijers-Heijboer EJ, Verhoog LC, Brekelmans CT, Seynaeve C,
Tilanus-Linthorst MM, Wagner A, Dukel L, Devilee P , van den
Ouweland AM, van Geel AN and Klijn JG. Presymptomatic DNA
testing and prophylactic surgery in families with a BRCA 1 or
BRCA 2 mutation. Lancet 2000; 355: 2015-2020.
2. Brekelmans CT, Seynaeve C, Bartels CC, Tilanus-Linthorst MM,
Meijers-Heijboer EJ, Crepin CM, van Geel AA, Menke M, Verhoog
LC, van den Ouweland A, Obdeijn IM, Klijn JG; Rotterdam
Committee for Medical and Genetic Counseling. Effectiveness of
breast cancer surveillance in BRCA1/2 gene mutation carriers and
women with high family risk. J Clin Oncol 2001; 19: 924-930.
3. Scheuer L, Kauff N, Robson M, Kelly B, Barakat R, Satagopan J,
Ellis N, Hensley M, Boyd J, Borgen P , Norton L and Offit K. Outcome
of Preventive Surgery and Screening for Breast and Ovarian Cancer
in BRCA Mutation Carriers. J Clin Oncol 2002; 20: 1260-1268.
4. Kuhl CK, Schmutzler RK, Leutner CC, Kempe A, Wardelmann E,
Hocke A, Maringa M, Pfeifer U, Krebs D and Schild HH. Breast
MR Imaging screening in 192 women proved or suspected to beH He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2004; 2(1) 18
Mieke Kriege et al.
carriers of a breast cancer susceptibility gene: preliminary results.
Radiology 2000; 215: 267-279.
5. Warner E, Plewes DB, Shumak RS, Catzavelos GC, Di Prospero LS,
Yaffe MJ, Goel V, Ramsay E, Chart PL, Cole DE, Taylor GA, Cutrara
M, Samuels TH, Murphy JP , Murphy JM and Narod SA. Comparison
of breast magnetic resonance imaging, mammography, and
ultrasound for surveillance of women at high risk for hereditary
breast cancer. J Clin Oncol 2001; 19: 3524-3531.
6. Stoutjesdijk MJ, Boetes C, Jager GJ, Beex L, Bult P , Hendriks JH, Laheij
RJ, Massuger L, van Die LE, Wobbes T and Barentsz JO. Magnetic
resonance imaging and mammography in women with a hereditary
risk of breast cancer. J Natl Cancer Inst 2001; 93: 1095-1102.
7. Kriege M, Brekelmans CT, Boetes C, Rutgers EJ, Oosterwijk JC,
Tollenaar RA, Manoliu RA, Holland R, de Koning HJ and Klijn JG.
MRI screening for breast cancer in women with familial or genetic
predisposition: design of the Dutch National Study. Familial
Cancer 2001; 1: 163-168. 
8. Brown J, Buckley D and Coulthard A. Magnetic resonance
imaging screening in women at genetic risk of breast cancer:
imaging and analysis protocol for the UK multicentre study. Magn
Res Imag 2000; 18: 765-776.